Prévisions
L'objectif de cours moyen des analystes est de 10,02 € (+186,29 %). La médiane est de 9,11 € (+160,29 %).
| Acheter |
11 |
| Conserver |
3 |
| Vendre |
7 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
MannKind achieves positive phase‑1b results for inhaled nintedanib in IPF
MannKind reports positive topline results from the randomized, double‑blind phase‑1b study INFLO‑1 of inhaled nintedanib as a dry powder in patients with idiopathic pulmonary fibrosis (IPF). The 27‑patient study showed no serious adverse events, no drug‑related gastrointestinal side effects, no bronchospasms and no discontinuations or dose reductions; cough was mostly mild and transient. Overall, IPF patients received about 450 inhalations; combined with phase‑1a, 48 people were treated, 18 of them with IPF. The global phase‑2 study INFLO‑2 to further evaluate nintedanib DPI is currently recruiting and is expected to enroll around 210 participants. » Plus sur de.investing.com
Wells Fargo upgrades MannKind after pediatric Afrezza approval, calls commercial potential a “show‑me story”
Wells Fargo raised its price target on MannKind to $11 and kept an Overweight rating, citing FDA approval of Afrezza for patients aged 6 and older and supportive INHALE‑1 data. The approval expands Afrezza’s market to pediatric patients and caregivers. MannKind also highlighted potential near‑term upside from up to $35 million in development milestones, a 10% royalty on net sales and its role as sole manufacturer of Tyvaso DPI. » Plus sur finance.yahoo.com
MannKind completes patient recruitment for INFLO‑1 and starts global phase‑2 for Nintedanib DPI
MannKind has completed randomization of patients in the phase‑1b trial INFLO‑1 and has enrolled the first patient in the global phase‑2 trial INFLO‑2 for Nintedanib DPI. INFLO‑1 evaluates safety, tolerability and pharmacokinetics; results are expected in Q3 2026. INFLO‑2 aims to recruit about 210 participants at roughly 85 sites in a randomized, double‑blind 1:1:1 design over 12 weeks (with a 24‑week open extension) for dose finding and safety assessment. » Plus sur de.investing.com
MannKind: shareholders re-elect nine directors, approve compensation and auditor
At the annual general meeting, shareholders re-elected all nine nominated MannKind directors and voted in an advisory capacity to approve the board’s compensation. Deloitte & Touche was confirmed as the independent auditor for the fiscal year ending December 31, 2026. In quarterly results, MannKind reported a 15% revenue rise to $90 million, mainly driven by FUROSCIX following the acquisition of scPharmaceuticals, but missed the EPS forecast of -$0.01 with a non-GAAP net loss of $0.02 per share. » Plus sur de.investing.com
MannKind records Q1 revenue up 15% and sees three near-term regulatory catalysts
MannKind reported Q1 2026 revenue of $90 million (up 15% year-over-year), driven by the integration of FUROSCIX; the adjusted non-GAAP result showed a loss of $6.9 million. Management emphasizes strategic diversification away from a one-product model and identifies three imminent value drivers: Afrezza Pediatrics (PDUFA May 29), the FUROSCIX ReadyFlow autoinjector (PDUFA July 26), and nintedanib DPI with topline data in Q3 and the start of Phase 2 recruitment. The partnership with United Therapeutics for Ralinepag DPI was also expanded, including an upfront payment and milestones, and the revenue outlook for FUROSCIX in 2026 remains $110–120 million. » Plus sur de.investing.com
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursEn 2022, MannKind Co. a déjà versé 7,52 € de dividendes. Le dernier versement a eu lieu en septembre 2022.
Données financières
Au dernier trimestre, MannKind Co. a réalisé un chiffre d'affaires de 89,94 M € et un bénéfice net de -20,5 M €
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 89,94 M | 28,51 % |
| Bénéfice brut | 69,18 M | 31,09 % |
| Bénéfice net | -20,5 M | 401,33 % |
| EBITDA | -4,73 M | 131,10 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 1,15 Md € |
Nombre d'actions | 321,64 M |
Plus haut/bas sur 52 semaines | 5,93 € - 2,03 € |
| Dividendes | Non |
Bêta | 1,09 |
Ratio P/E | -16,62 |
Ratio PEG | 0,16 |
Ratio P/B | -33,64 |
Ratio P/S | 3,05 |
Profil de l'entreprise
MannKind Corporation, une société biopharmaceutique, se concentre sur le développement et la commercialisation de produits thérapeutiques inhalés destinés aux maladies endocriniennes et aux maladies pulmonaires orphelines aux États-Unis. Elle propose Afrezza, une insuline inhalée utilisée pour améliorer le contrôle glycémique chez les adultes atteints de diabète. Elle fait également la promotion de Thyquidity auprès des endocrinologues adultes et pédiatriques ainsi que d'autres professionnels de santé pour le traitement de l'hypothyroïdie. La société a conclu un accord de licence et de collaboration avec United Therapeutics Corporation. Elle a également un accord avec NRx Pharmaceuticals pour développer une formulation en poudre sèche de ZYESAMI (aviptadil), une forme synthétique du peptide intestinal vasoactif humain destinée à aider à protéger les cellules contre les affections inflammatoires. MannKind Corporation a été constituée en 1991 et son siège social se trouve à Westlake Village, en Californie.
| Nom | MannKind Co. |
| PDG | Michael E. Castagna |
| Siège social | Danbury,
ca États-Unis |
| Site web | |
| Secteur | Matériaux |
| Industrie | Produits chimiques |
| Introduction en bourse | 28/07/2004 |
| Employés | 592 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | MNKD |
Frankfurt | NNFN.F |
Düsseldorf | NNFN.DU |
SIX | NNFN.SW |
München | NNFN.MU |